Key Takeaways:
Arvinas reported Q2 revenue of $249.7 million, up from $22.4 million a year earlier, after the FDA approved its first-ever PROTAC degrader VEPPANU.
"The approval of VEPPANU, the first ever for a PROTAC degrader, was a significant achievement for the Company, and our subsequent licensing of VEPPANU to Rigel Pharmaceuticals promises to unlock its commercial potential," Randy Teel, President and CEO at Arvinas, said.
Revenue included $62.5 million from the Rigel license agreement and a $50 million development milestone from Pfizer tied to the FDA approval. GAAP R&D expenses fell to $52.6 million from $68.6 million, while G&A declined to $24.0 million from $25.3 million. Cost of license revenue rose to $9.0 million from zero, reflecting expenses under the amended Yale License Agreement. The company posted net income of $169.4 million, or $2.58 per diluted share, versus a net loss of $61.2 million a year earlier. Consensus estimates had called for revenue of $32.54 million and a loss of $0.44 per share.
Shares rose 6.08 percent to $8.55 after the release. The company ended June with $567.9 million in cash and securities, down from $685.4 million at year-end, with cash used in operations of $114.3 million in the first half. Management projects funding into the second half of 2028.
VEPPANU (vepdegestrant), developed with Pfizer, received FDA approval for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. The National Comprehensive Cancer Network added vepdegestrant as a Category 2A treatment option for the same patient population. Arvinas subsequently out-licensed global development, manufacturing, and commercialization rights to Rigel Pharmaceuticals.
The company is concentrating resources on its early-stage oncology and neurology pipeline. Arvinas plans to share initial data from ARV-806, its KRAS G12D degrader, in the second half of 2026, and initiate a Phase 1 trial for ARV-6723, an HPK1 degrader targeting solid tumors, in the third quarter. Data from ARV-393, ARV-102, and ARV-027 are expected over the next 12 months. ARV-393 targets BCL6 for relapsed/refractory non-Hodgkin lymphoma, while ARV-102 targets LRRK2 for Parkinson's disease and ARV-027 targets polyQ-AR for spinal-bulbar muscular atrophy.
Analysts hold an average price target of $14.79 on Arvinas, implying 84 percent upside from the current price of $8.55, with a consensus recommendation of "Outperform" from 17 brokerage firms. GuruFocus estimates a GF Value of $10.79, suggesting 34 percent upside.
The FDA approval confirms Arvinas' PROTAC platform and the Rigel deal provides near-term cash while reducing commercialization risk. Investors will watch for initial ARV-806 data in the second half of 2026 and the ARV-6723 Phase 1 initiation in the third quarter as the next events to move the stock.
This article is for informational purposes only and does not constitute investment advice.
